HBP-assay is a market-launched diagnostic method for predicting severe sepsis at emergency wards. In December 2012, Hansa Medical's partner, Axis-Shield Diagnostics Ltd, launched a CE marked version of the assay. The license with Axis-Shield Diagnostics Limited entitles Hansa Medical to receive royalties from license fees paid to Axis-Shield Diagnostics Limited and royalties from sales made by Axis-Shield Diagnostics Limited. Axis-Shield Diagnostics Limited regards China as a significant potential market for the HBP test and is currently working with Hangzhou Joinstar Biomedical Technology Co Ltd to attest the performance of the HBP test in a large multi-centre study. It is estimated that there are between 20-30 million cases of sepsis in China annually.

Hangzhou Joinstar Biomedical Technology Co. Ltd. is a technology company which develops, manufactures and distributes in-vitro diagnostic products to the Hospital and laboratory sectors in China. In 2014 it had a turnover of around 70 million US Dollars.

“It is great to see that our collaboration with Axis-Shield Diagnostics Limited and their efforts in product development, distribution and sublicensing is starting to bear fruit”, says Emanuel Björne, Corporate Development Director at Hansa Medical AB.

The information in this press release is disclosed pursuant to the Securities Markets Act or the Financial Instruments Trading Act. The information was released for public disclosure on February 18, 2015 at 13.00.